The DOI matches its Crossref record; 93 of the 94 references it cites were found in a registry or an index.
Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses
Open accessAbstract
We show that DNA methyltransferase inhibitors (DNMTis) upregulate immune signaling in cancer through the viral defense pathway. In ovarian cancer (OC), DNMTis trigger cytosolic sensing of double-stranded RNA (dsRNA) causing a type I interferon response and apoptosis. Knocking down dsRNA sensors TLR3 and MAVS reduces this response 2-fold and blocking interferon beta or its receptor abrogates it. Upregulation of hypermethylated endogenous retrovirus (ERV) genes accompanies the response and ERV overexpression activates the response. Basal levels of ERV and viral defense gene expression significantly correlate in primary OC and the latter signature separates primary samples for multiple tumor types from The Cancer Genome Atlas into low versus high expression groups. In melanoma patients treated with an immune checkpoint therapy, high viral defense signature expression in tumors significantly associates with durable clinical response and DNMTi treatment sensitizes to anti-CTLA4 therapy in a pre-clinical melanoma model.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The IFN-I response could also expose the tumor cells to surveillance by the immune system96, 97.”
From The role of retrotransposable elements in ageing and age-associated diseases (2021) · cites this paper as [97]
The cited source says what the claim attributes to it.
In the citing paper
“multiple studies have shown that DNA demethylating agents among other epigenetic modulators can induce a type I IFN response in cancer cells through the de-repression of endogenous retroviruses (ERVs) and activation of the MDA5-MAVS pathway38–40.”
From Epigenetic state determines the in vivo efficacy of STING agonist therapy (2023) · cites this paper as [38]
The cited source says what the claim attributes to it.
In the citing paper
“DAC treatment could induce expression of retrotransposons normally silenced by DNA methylation, which could also augment tumor immunogenicity10–14,99.”
From Multi-omic analysis of hepatocellular carcinoma reveals aberrant cis-regulatory changes and dysregulated retrotransposons with prognostic potential (2025) · cites this paper as [12]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“inactivated typical enhancers were associated with collagen fibril organization and chemotaxis GO terms and were enriched for binding motifs of immune-related TFs, including STAT1 (Fig. 2a, b)12,13.”
From Multi-omic analysis of hepatocellular carcinoma reveals aberrant cis-regulatory changes and dysregulated retrotransposons with prognostic potential (2025) · cites this paper as [12]
Experimental — accuracy not yet measuredIn the citing paper
“inhibiting EZH2 activity can either positively or negatively influence tumour-specific immune responses by modulating both tumour immunogenicity and the function of infiltrating T-cells, NK-cells and macrophages 196 .”
From The roles of DNA, RNA and histone methylation in ageing and cancer (2019) · cites this paper as [196]
In the citing paper
“derepression of endogenous retroviral elements coupled to robust type I and type III IFN signaling”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Chiappinelli et al., 2015
In the citing paper
“Certainly, this dual epigenetic targeting may influence additional antiproliferative mechanisms and further enhance antitumor surveillance by the immune system (Chiappinelli et al., 2015).”
From HDACs and the epigenetic plasticity of cancer cells: target the complexity (2022) · cites this paper as Chiappinelli et al., 2015
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationThe blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Self-citationSafety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citationPD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Self-citationSafety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Self-citationMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Self-citationCancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking
Wilkerson, M. D., & Hayes, D. N. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq170 · Cited by 5,645
Cited by
Sorted by citations
Items 701–800 of 1,003
Fragale, A., Romagnoli, G., Licursi, V., Buoncervello, M., Vecchio, G. D., Giuliani, C., Parlato, S., Leone, C., Angelis, M. D., Canini, I., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0080 · Cited by 33
Barbieri, D., Elvira‐Matelot, E., Pelinski, Y., Genève, L., de Laval, B., Yogarajah, G., Pecquet, C., Constantinescu, S. N., & Porteu, F. (2018) · The Journal of Experimental Medicine · doi:10.1084/jem.20170997 · Cited by 41
Immune checkpoint-based therapy in myeloid malignancies: a promise yet to be fulfilled
Bewersdorf, J. P., Stahl, M. F., & Zeidan, A. M. (2019) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1589374 · Cited by 35
Recent Advances in the Targeting of Epigenetic Regulators in B-Cell Non-Hodgkin Lymphoma
Ribeiro, M. L., Reyes-Garau, D., Armengol, M., Fernández-Serrano, M., & Roué, G. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00986 · Cited by 34
Greiner, J., Götz, M., Bunjes, D. W., Hofmann, S., & Wais, V. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm9010039 · Cited by 33
Kazachenka, A., Young, G. R., Attig, J., Kordella, C., Lamprianidou, E., Zoulia, E., Vrachiolias, G., Papoutselis, M. K., Bernard, E., Papaemmanuil, E., et al. (2019) · Genome Medicine · doi:10.1186/s13073-019-0707-x · Cited by 33
DNA methylation and histone variants in aging and cancer
Mangelinck, A., & Mann, C. (2021) · International review of cytology · doi:10.1016/bs.ircmb.2021.06.002 · Cited by 35
Stricker, E., Peckham‐Gregory, E. C., & Scheurer, M. E. (2023) · Journal of Virology · doi:10.1128/jvi.00059-23 · Cited by 33
Cancer Stem Cells: Devil or Savior—Looking behind the Scenes of Immunotherapy Failure
Castagnoli, L., Santis, F. D., Volpari, T., Vernieri, C., Tagliabue, E., Nicola, M. D., & Pupa, S. M. (2020) · Cells · doi:10.3390/cells9030555 · Cited by 33
Nigam, N., Bernard, B., Sevilla, S., Kim, S., Dar, M. S., Tsai, D., Robbins, Y. L., Burkitt, K., Sievers, C. M., Allen, C. T., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112823 · Cited by 37
Mitotic perturbation is a key mechanism of action of decitabine in myeloid tumor treatment
Yabushita, T., Chinen, T., Nishiyama, A., Asada, S., Shimura, R., Isobe, T., Yamamoto, K., Sato, N., Enomoto, Y., Tanaka, Y., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113098 · Cited by 32
Giorgio, E. D., Ranzino, L., Tolotto, V., Dalla, E., Burelli, M., Gualandi, N., & Brancolini, C. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06548-2 · Cited by 32
Wang, R., Dong, X., Zhang, X., Liao, J., Cui, W., & Li, W. (2025) · International Journal of Biological Sciences · doi:10.7150/ijbs.103877 · Cited by 37
Epigenetic Strategies to Boost Cancer Immunotherapies
Barrero, M. J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061108 · Cited by 33
Beck, L. D., Melhaoui, S., Veirman, K. D., Menu, E., Bruyne, E. D., Vanderkerken, K., Breckpot, K., & Maes, K. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1484981 · Cited by 32
Epigenetics of oral and oropharyngeal cancers (Review)
Russo, D., Merolla, F., Varricchio, S., Salzano, G., Zarrilli, G., Mascolo, M., Strazzullo, V., Crescenzo, R. M. D., Celetti, A., & Ilardi, G. (2018) · Biomedical Reports · doi:10.3892/br.2018.1136 · Cited by 32
Immuno-Oncology Biomarkers for Personalized Immunotherapy in Breast Cancer
Vafaizadeh, V., & Barekati, Z. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00162 · Cited by 34
Domankevich, V., Efrati, M., Schmidt, M. T., Glikson, E., Mansour, F., Shai, A., Cohen, A., Zilberstein, Y., Flaisher, E., Galalae, R. M., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00990 · Cited by 32
Loss of PHF8 induces a viral mimicry response by activating endogenous retrotransposons
Liu, Y., Hu, L., Wu, Z., Yuan, K., Hong, G., Lian, Z., Feng, J., Li, N., Li, D., Wong, J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39943-y · Cited by 32
Epigenetic Regulation of Immune Checkpoints: Another Target for Cancer Immunotherapy?
ALI, M. A. M., Matboli, M., Tarek, M., Reda, M., Kamal, K. M., Nouh, M., Ashry, A. M., El-Bab, A. F., Mesalam, H. A., Shafei, A., et al. (2016) · Immunotherapy · doi:10.2217/imt-2016-0111 · Cited by 33
Nucleic Acid Sensing Machinery: Targeting Innate Immune System for Cancer Therapy
Iurescia, S., Fioretti, D. P., & Rinaldi, M. (2017) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574892812666171030163804 · Cited by 31
Du, J., Kageyama, S., Yamashita, R., Tanaka, K., Okumura, M., Motegi, A., Hojo, H., Nakamura, M., Hirata, H., Sunakawa, H., et al. (2023) · Communications Biology · doi:10.1038/s42003-023-05080-x · Cited by 33
Regulation and function of transposable elements in cancer genomes
Lee, M., Ahmad, S. F., & Xu, J. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05195-2 · Cited by 34
Disruption of cellular plasticity by repeat RNAs in human pancreatic cancer
You, E., Danaher, P. J., Lu, C., Sun, S., Zou, L. S., Phillips, I. E., Rojas, A. S., Ho, N. I., Song, Y., Raabe, M. J., et al. (2024) · Cell · doi:10.1016/j.cell.2024.09.024 · Cited by 31
Self-citationBuoncervello, M., Romagnoli, G., Buccarelli, M., Fragale, A., Toschi, E., Parlato, S., Lucchetti, D., Macchia, D., Spada, M., Canini, I., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8379 · Cited by 31
PARP-inhibitor-induced synthetic lethality for acute myeloid leukemia treatment
Zhao, L., & So, C. W. E. (2016) · Experimental Hematology · doi:10.1016/j.exphem.2016.07.007 · Cited by 32
Huang, H., Wu, P., Zhang, S., Shang, Q., Yin, H., Hou, Q., Zhong, J., & Guo, X. (2019) · BMC Genomics · doi:10.1186/s12864-019-6146-7 · Cited by 31
Epigenetic Reprogramming for Targeting IDH-Mutant Malignant Gliomas
Park, J., & Turcan, Ş. (2019) · Cancers · doi:10.3390/cancers11101616 · Cited by 33
Dahn, M. L., Cruickshank, B. M., Jackson, A. J., Dean, C. A., Holloway, R. W., Hall, S. R., Coyle, K. M., Maillet, H., Waisman, D. M., Goralski, K. B., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0745 · Cited by 32
Tossberg, J. T., Heinrich, R. M., Farley, V. M., Crooke, P. S., & Aune, T. M. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2000384 · Cited by 31
Singh, M., Cai, H., Bunse, M., Feschotte, C., & Izsvák, Z. (2020) · Viruses · doi:10.3390/v12111303 · Cited by 32
Natoli, M., Gallon, J., Lu, H., Amgheib, A., Pinato, D. J., Mauri, F. A., Marafioti, T., Akarca, A. U., Ullmo, I., Ip, J., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001519 · Cited by 33
Berglund, A., Putney, R. M., Hamaidi, I., & Kim, S. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00612-z · Cited by 33
Chromatin states shaped by an epigenetic code confer regenerative potential to the mouse liver
Zhang, C., Macchi, F., Magnani, E., & Sadler, K. C. (2021) · Nature Communications · doi:10.1038/s41467-021-24466-1 · Cited by 32
Mammalian antiviral systems directed by small RNA
Takahashi, T., Heaton, S. M., & Parrish, N. F. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1010091 · Cited by 31
Chromatin remodeling (SWI/SNF) complexes, cancer, and response to immunotherapy
Krishnamurthy, N., Kato, S., Lippman, S. M., & Kurzrock, R. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004669 · Cited by 31
RNA mis-splicing drives viral mimicry response after DNMTi therapy in SETD2-mutant kidney cancer
Li, H., Jang, H. J., Rohena-Rivera, K., Liu, M., Gujar, H., Kulchycki, J. R., Zhao, S., Billet, S., Zhou, X., Weisenberger, D. J., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112016 · Cited by 31
Self-citationGeyer, K. K., Munshi, S. E., Vickers, M. J., Squance, M., Wilkinson, T., Berrar, D., Chaparro, C., Swain, M., & Hoffmann, K. F. (2018) · International Journal for Parasitology Drugs and Drug Resistance · doi:10.1016/j.ijpddr.2018.03.006 · Cited by 31
Translational genomics of malignant rhabdoid tumours: Current impact and future possibilities
Finetti, M. A., Grabovska, Y., Bailey, S., & Williamson, D. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.017 · Cited by 31
Greve, G., Schüler, J. B., Grüning, B. A., Berberich, B., Stomper, J., Zimmer, D., Gutenkunst, L., Bönisch, U., Meier, R., Blagitko‐Dorfs, N., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-1430 · Cited by 31
Burns, K. H. (2022) · Science · doi:10.1126/science.abl7399 · Cited by 30
Epigenetic plasticity, selection, and tumorigenesis
Flavahan, W. A. (2020) · Biochemical Society Transactions · doi:10.1042/bst20191215 · Cited by 31
Germinal center output is sustained by HELLS-dependent DNA-methylation-maintenance in B cells
Cousu, C., Mulot, E., Smet, A. D., Formichetti, S., Lecoeuche, D., Ren, J., Muegge, K., Boulard, M., Weill, J., Reynaud, C., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41317-3 · Cited by 31
IDH1 mutation impairs antiviral response and potentiates oncolytic virotherapy in glioma
Chen, X., Liu, J., Li, Y., Zeng, Y., Wang, F., Cheng, Z., Duan, H., Pan, G., Yang, S., Chen, Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42545-3 · Cited by 30
Retrotransposons are co-opted to activate hematopoietic stem cells and erythropoiesis
Phan, J., Chen, B., Zhao, Z., Allies, G., Iannaccone, A., Paul, A., Cansiz, F., Spina, A., Leven, A., Gellhaus, A., et al. (2024) · Science · doi:10.1126/science.ado6836 · Cited by 31
Targeting METTL3 as a checkpoint to enhance T cells for tumour immunotherapy
Wu, K., Li, S., Hong, G., Dong, H., Tang, T., He, L., Jin, L., Lin, S., Ji, J., Hu, M., et al. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.70089 · Cited by 31
Liu, W.-C., Wei, Y., Chen, J., Xing, X., Jia, H., Yang, X., Huang, Y., Liu, X.-M., Xiao, K., Guo, X., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-60293-4 · Cited by 30
PARP1 depletion induces RIG-I-dependent signaling in human cancer cells
Ghosh, R., Roy, S., & Franco, S. (2018) · PLoS ONE · doi:10.1371/journal.pone.0194611 · Cited by 30
Epigenetic therapy in hematological cancers
Dimopoulos, K., & Grønbæk, K. (2019) · Apmis · doi:10.1111/apm.12906 · Cited by 30
Gruber, E., Franich, R. L., Shortt, J., Johnstone, R. W., & Kats, L. M. (2020) · Leukemia · doi:10.1038/s41375-020-0973-z · Cited by 30
McDonald, J. I., Diab, N., Arthofer, E., Hadley, M. M., Kanholm, T., Rentia, U., Gomez, S., Yu, A. Y. C., Grundy, E. E., Cox, O. L., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-4243 · Cited by 35
Self-citationHow Influenza A Virus NS1 Deals with the Ubiquitin System to Evade Innate Immunity
Lamotte, L.-A., & Tafforeau, L. (2021) · Viruses · doi:10.3390/v13112309 · Cited by 33
Müller, M. D., Holst, P. J., & Nielsen, K. N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031330 · Cited by 34
Transposable Elements Co-Option in Genome Evolution and Gene Regulation
Gasparotto, E., Burattin, F. V., Gioia, V. D., Panepuccia, M., Ranzani, V., Marasca, F., & Bodega, B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032610 · Cited by 32
Pharmacological DNA demethylation: Implications for cancer immunotherapy
Roulois, D., Yau, H. L., & Carvalho, D. D. D. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1090077 · Cited by 30
Genome-Wide Association Studies and Epigenome-Wide Association Studies Go Together in Cancer Control
Verma, M. (2016) · Future Oncology · doi:10.2217/fon-2015-0035 · Cited by 30
Methyltransferase inhibitors for modulation of the epigenome and beyond
Schapira, M., & Arrowsmith, C. H. (2016) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2016.05.030 · Cited by 31
Extraordinary Cancer Epigenomics: Thinking Outside the Classical Coding and Promoter Box
Murtha, M. J., & Esteller, M. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.08.004 · Cited by 30
Serganova, I. S., Chakraborty, S., Yamshon, S., Isshiki, Y., Bucktrout, R., Melnick, A. M., Béguelin, W., & Zappasodi, R. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.805195 · Cited by 30
Kanholm, T., Rentia, U., Hadley, M. M., Karlow, J. A., Cox, O. L., Diab, N., Bendall, M. L., Dawson, T., McDonald, J. I., Xie, W., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-3485 · Cited by 33
Self-citationEpigenetics and immunotherapy in colorectal cancer: progress and promise
Dang, T., Guan, X., Cui, L., Ruan, Y., Chen, Z., Zou, H., Lan, Y., Liu, C., & Zhang, Y. (2024) · Clinical Epigenetics · doi:10.1186/s13148-024-01740-9 · Cited by 29
Zhuang, S., Li, F., Wang, L., Lai, Z., Li, D., Wu, H., Wu, J., Qu, J., Zhang, X., Zhang, M., et al. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02145-8 · Cited by 30
5-Azacytidine Potentiates Anti-tumor Immunity in a Model of Pancreatic Ductal Adenocarcinoma
Ebelt, N. D., Zuniga, E., Johnson, B. L., Diamond, D. J., & Manuel, E. R. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00538 · Cited by 30
Ghosh, S., Guimaraes, J. C., Lanzafame, M., Schmidt, A., Syed, A. P., Dimitriades, B., Börsch, A., Ghosh, S., Mittal, N., Montavon, T. C., et al. (2020) · The EMBO Journal · doi:10.15252/embj.2019103922 · Cited by 29
Chua, V. Y. L., Mattei, J., Han, A., Johnston, L., LiPira, K., Selig, S. M., Carvajal, R. D., Aplin, A. E., & Patel, S. P. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2536 · Cited by 27
Single-nucleotide methylation specifically represses type I interferon in antiviral innate immunity
Gao, Z., Li, W., Mao, X.-T., Huang, T., Wang, H., Li, Y., Liu, B.-Q., Zhong, J.-Y., Chai, R., Jin, J., et al. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20201798 · Cited by 28
Weyerer, V., Strissel, P. L., Stöhr, C., Eckstein, M., Wach, S., Taubert, H. W., Brandl, L., Geppert, C. I., Wullich, B., Cynis, H., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.657187 · Cited by 32
Self-citationHu, N., Li, W., Hong, Y., Zeng, Z., Zhang, J., Wu, X., Zhou, K., & Wu, F. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.12.006 · Cited by 29
Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma
Wong, J., Gruber, E., Maher, B. M., Waltham, M. C., Sabouri-Thompson, Z., Jong, I., Luong, Q., Levy, S. M., Kumar, B., Brasacchio, D., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01571-8 · Cited by 29
Mutant p53 gain of function mediates cancer immune escape that is counteracted by APR-246
Zhou, X., Sanz, G., Zhan, Y., Oliveira, M. M. S., Rezaei, S., Singh, M., Peuget, S., Westerberg, L. S., Johnsen, J. I., & Selivanova, G. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01971-8 · Cited by 31
Anichini, A., Molla, A., Nicolini, G., Perotti, V., Sgambelluri, F., Covre, A., Fazio, C., Lofiego, M. F., Giacomo, A. M. D., Coral, S., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02529-5 · Cited by 30
Saito, Y., Nakaoka, T., Sakai, K., Muramatsu, T., Toshimitsu, K., Kimura, M., Kanai∥, T., Sato, T., & Saito, H. (2016) · Scientific Reports · doi:10.1038/srep25311 · Cited by 29
Li, L., Ma, B. B. Y., Chan, A. T. �., Chan, F. K. L., Murray, P. G., & Tao, Q. (2018) · Pathogens · doi:10.3390/pathogens7030063 · Cited by 29
Khan, A., & Zhang, X. (2022) · Bioengineering · doi:10.3390/bioengineering9080406 · Cited by 29
Zhou, Y., Zhang, Y., Li, M., Ming, T., Zhang, C., Huang, C., Li, J., Li, F., Li, H. ‐., Zhao, E., et al. (2024) · Science Immunology · doi:10.1126/sciimmunol.ado8758 · Cited by 30
Self-citationDesai, N., Sajed, D. P., Arora, K. S., Solovyov, A., Rajurkar, M., Bledsoe, J. R., Sil, S., Amri, R., Tai, E. C., Mackenzie, O., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.91078 · Cited by 27
Targeting Cancer through the Epigenetic Features of Telomeric Regions
Vaquero-Sedas, M. I., & Vega-Palas, M. A. (2019) · Trends in Cell Biology · doi:10.1016/j.tcb.2018.12.006 · Cited by 28
Kogan, A. A., Lapidus, R. G., Baer, M. R., & Rassool, F. V. (2019) · Advances in cancer research · doi:10.1016/bs.acr.2018.12.005 · Cited by 28
Lavasanifar, A., Sharp, C. N., Korte, E. A., Yin, T., Hosseinnejad, K., & Jortani, S. A. (2019) · Clinica Chimica Acta · doi:10.1016/j.cca.2019.02.015 · Cited by 29
Sun, S., Frontini, F., Qi, W., Hariharan, A., Ronner, M., Wipplinger, M., Blanquart, C., Rehrauer, H., Fonteneau, J., & Felley‐Bosco, E. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.03.004 · Cited by 30
Endogenous reverse transcriptase and RNase H-mediated antiviral mechanism in embryonic stem cells
Wu, J., Wu, C., Xing, F., Cao, L., Zeng, W., Guo, L., Li, P., Zhong, Y., Jiang, H., Luo, M., et al. (2021) · Cell Research · doi:10.1038/s41422-021-00524-7 · Cited by 26
Shah, A. H., Govindarajan, V., Doucet-O’Hare, T. T., Rivas, S. R., Ampie, L., DeMarino, C., Banasavadi‐Siddegowda, Y., Zhang, Y., Johnson, K. R., Almsned, F. M., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-10914-5 · Cited by 28
Grandi, N., Erbì, M. C., Scognamiglio, S., & Tramontano, E. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.02516-22 · Cited by 28
Multifaceted roles of RNA editing enzyme ADAR1 in innate immunity
Jarmoskaite, I., & Li, J. B. (2024) · RNA · doi:10.1261/rna.079953.124 · Cited by 26
Su, P., Liu, Y., Chen, T., Xue, Y., Zeng, Y., Zhu, G., Chen, S., Teng, M., Ci, X., Guo, M., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01874-9 · Cited by 31
Reactivation of retrotransposable elements is associated with environmental stress and ageing
Valle, F. D., Reddy, P., Aguirre-Vázquez, A., & Belmonte, J. C. I. (2025) · Nature Reviews Genetics · doi:10.1038/s41576-025-00829-y · Cited by 27
Yang, J., Zhang, Y., & Song, H. (2019) · Aging · doi:10.18632/aging.102197 · Cited by 27
Nutritional Epigenetics in Cancer
Barrero, M. J., Cejas, P., Long, H. W., & de Molina, A. R. (2022) · Advances in Nutrition · doi:10.1093/advances/nmac039 · Cited by 27
Tessier, S., Ferhi, O., Geoffroy, M., González‐Prieto, R., Canat, A., Quentin, S., Pla, M., Niwa‐Kawakita, M., Bercier, P., Rérolle, D., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33147-6 · Cited by 30
Hargadon, K. M. (2023) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-04689-9 · Cited by 30
Cortesi, A., Gandolfi, F., Arco, F., Chiaro, P. D., Valli, E., Polletti, S., Noberini, R., Gualdrini, F., Attanasio, S., Citron, F., et al. (2024) · Science Advances · doi:10.1126/sciadv.adk5386 · Cited by 29
NETs: organ-related epigenetic derangements and potential clinical applications
Cives, M., Simone, V. D., Rizzo, F. M., & Silvestris, F. (2016) · Oncotarget · doi:10.18632/oncotarget.10598 · Cited by 26
A to I editing in disease is not fake news
Bajad, P., Jantsch, M. F., Keegan, L. P., & O’Connell, M. A. (2017) · RNA Biology · doi:10.1080/15476286.2017.1306173 · Cited by 27
Refining PD-1/PD-L1 assessment for biomarker-guided immunotherapy: A review
Zdrenka, M., Kowalewski, A., Ahmadi, N., Sadiqi, R. U., Chmura, Ł., Borowczak, J., Maniewski, M., & Szylberg, Ł. (2023) · Biomolecules and Biomedicine · doi:10.17305/bb.2023.9265 · Cited by 30
Epigenetic therapy: Research progress of decitabine in the treatment of solid tumors
Ye, C., Jiang, N., Zheng, J., Zhang, S., Zhang, J., & Zhou, J. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.189066 · Cited by 30
Retroelement decay by the exonuclease XRN1 is a viral mimicry dependency in cancer
Hosseini, A., Lindholm, H. T., Chen, R. E., Mehdipour, P., Marhon, S. A., Ishak, C. A., Moore, P. C., Classon, M., Gioacchino, A. D., Greenbaum, B. D., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.113684 · Cited by 30
Stem cell activity-coupled suppression of endogenous retrovirus governs adult tissue regeneration
Lyu, Y., Kim, S., Humphrey, E., Nayak, R., Guan, Y., Liang, Q., Kim, K. H., Tan, Y., Dou, J., Sun, H., et al. (2024) · Cell · doi:10.1016/j.cell.2024.10.007 · Cited by 31
Xie, B., Becker, E., Stuparević, I., Wéry, M., Szachnowski, U., Morillon, A., & Primig, M. (2019) · RNA Biology · doi:10.1080/15476286.2019.1581596 · Cited by 25
DNA methylation changes following DNA damage in prostate cancer cells
Sutton, L. P., Jeffreys, S. A., Phillips, J. L., Taberlay, P. C., Holloway, A. F., Ambrose, M., Joo, J. E., Young, A., Berry, R., Skala, M., et al. (2019) · Epigenetics · doi:10.1080/15592294.2019.1629231 · Cited by 26
CAR T-Cell Cancer Therapy Targeting Surface Cancer/Testis Antigens
Jakobsen, M. K., & Gjerstorff, M. F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01568 · Cited by 26
Metadata
- Authors
- Chiappinelli, K. B., Strissel, P. L., Desrichard, A., Li, H., Henke, C., Akman, B., Hein, A., Rote, N. S., Cope, L. M., Snyder, A., Makarov, V., Buhu, S., Slamon, D. J., Wolchok, J. D., Pardoll, D. M., Beckmann, M. W., Zahnow, C. A., Merghoub, T., Chan, T. A., Baylin, S. B., & Strick, R.
- Affiliations
- Johns Hopkins University (US)
- Universitätsklinikum Erlangen (DE)
- Memorial Sloan Kettering Cancer Center (US)
- Case Western Reserve University (US)
- University of California, Los Angeles (US)
- Corresponding author
- Baylin, Stephen B.
- Strick, Reiner
- ORCID
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2015-08
- Volume
- 162
- Issue
- 5
- Pages
- 974-986
- ISSN
- 0092-8674 (ISSN-L)
- PMC
- PMC4556003
- OpenAlex
- W1953890763
- Cited by
- 2,022
- References
- 94
- Citations by year
- 2026: 193 · 2025: 188 · 2024: 211 · 2023: 209 · 2022: 225 · 2021: 250 · 2020: 184 · 2019: 163 · 2018: 161 · 2017: 133 · 2016: 93 · 2015: 10
- FWCI
- 65.10
- Type
- journal article
- Language
- en
- Update notices
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cell (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (P50CA058184, CA058184, F32CA183214, P30CA008748)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Keywords
- hypomethylating agents, DNA methylation, type I interferon response, double-stranded RNA sensing, endogenous retroviruses, ovarian cancer, melanoma, TLR3, MAVS, interferon-beta, apoptosis, immune checkpoint therapy, CTLA-4, tumor immune microenvironment, epigenetic reprogramming
- MeSH terms
- Animals, Azacitidine, Female, Humans, Immunotherapy, Interferon Type I, Lung Neoplasms, Melanoma, Mice, Inbred C57BL, Ovarian Neoplasms, RNA, Double-Stranded, DNA Modification Methylases, DNA Methylation, Endogenous Retroviruses, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
